Gastrointestinal and hepatic manifestations of COVID-19 infection: Lessons for practitioners

Table 10 Recommendations on use of immunosuppressive therapies in inflammatory bowel diseases[169]

	Asymptomatic infection	Mild to moderate infection	Severe or Critical infection
Corticosteroids	(1) Dose reduction of Prednisone to < 20 mg/d; and (2) Consider switching to budesonide.	(1) Discontinue; and (2) Taper in chronic users.
Immunomodulators (thiopurines, methotrexate)	(1) Consider risks vs benefits; and (2) Can resume after 14 d in asymptomatic patients or when test negative.
Biologicals	(1) Consider risks vs benefits; (2) Can resume after 14 d in asymptomatic patients or when test negative; (3) Can decrease infusion frequencies for infliximab and vedolizumab; and (4) Tofacitinib and JAK inhibitors should be discontinued.